MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Acute efficacy and tolerability of the COMT inhibitor opicapone

F. Gandor, D. Sykora, D. Gruber, G. Ebersbach (Beelitz-Heilstätten, Germany)

Meeting: 2018 International Congress

Abstract Number: 367

Keywords: COMT inhibitors

Session Information

Date: Saturday, October 6, 2018

Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: Evaluation of the acute efficacy and tolerability of Opicapone.

Background: Opicapone is a Catechol-O-Methyltransferase (COMT) inhibitor for the treatment of patients with idiopathic Parkinson’s Disease with motor fluctuations. The major studies on opicapone do not differentiate reactions occurring within the first days of treatment.

Methods: 88 patients with idiopathic Parkinson’s Disease with motor fluctuations were newly administered the COMT inhibitor opicapone during inpatient treatment at a specialized Parkinson’s Disease clinic. Acute efficacy (measured by Clinical Global Impression of change, CGI-c) and tolerability were assessed 3 days after starting treatment.

Results: After 3 days of treatment, 67% of the patients showed an improvement in the CGI-c score. Improvements occurred most often in patients which were exposed to a COMT-I for the first time (60.7 %), compared to those who were switched from entacapone (44.2 %) or tolcapone (37,5 %). The most common side effect was the emergence of, or increased, hyperkinesia (6.8 %) or hallucinations (14.7 %). The observed adverse reactions can be linked to the increased bioavailability of levodopa. Substance-specific side effects described for other COMT inhibitors (urine discolouration, diarrhea) were not observed.

Conclusions: Positive effects can be observed within in the first days of treatment with opicapone. Patients at risk for hyperkinesia or hallucinations should be carefully monitored for possible adverse events.

To cite this abstract in AMA style:

F. Gandor, D. Sykora, D. Gruber, G. Ebersbach. Acute efficacy and tolerability of the COMT inhibitor opicapone [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/acute-efficacy-and-tolerability-of-the-comt-inhibitor-opicapone/. Accessed July 3, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/acute-efficacy-and-tolerability-of-the-comt-inhibitor-opicapone/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley